Congress moves to ban abortion pill and sue providers into silence
H.R. 5646 — Restoring Safeguards for Dangerous Abortion Drugs Act · Filed by Mary Miller (R-IL) · 8 cosponsors · Introduced Sep 30, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill would force the FDA to revert mifepristone's safety rules to a stricter 2011 standard, ban all importation of the drug into the U.S., and create a federal private right of action allowing individuals to sue telehealth providers, pharmacies, and others who distribute mifepristone obtained through interstate or foreign commerce. The bill benefits anti-abortion advocates by tightening access to the drug; it harms patients seeking medication abortion and providers offering it.
Why we flagged it
The bill's operative mechanism is twofold: (1) regulatory rollback of FDA-approved safety protocols to a prior, more restrictive standard, and (2) creation of a private federal tort for harm allegedly caused by mifepristone, which expands liability exposure for providers and patients. Both mechanisms function to restrict access and increase legal risk.
- Section 4 creates a federal private right of action for harm from mifepristone use, unrelated to the bill's stated purpose of reverting REMS rules. This is a new tort mechanism, not a regulatory reversion.
What the text implies
- The private right of action in Section 4 may expose telehealth providers, pharmacies, and patients themselves to federal civil litigation for mifepristone use, even when the drug was obtained and used lawfully under current FDA rules. The causation standard ('attributable, in whole or in part') is broad and may invite speculative claims.
- Reverting to the 2011 REMS standard would likely require in-person dispensing and physician involvement, eliminating mail-based and telehealth access that has expanded since 2023. This effectively narrows the population able to access the medication.
- The ban on importation (Section 5) applies to mailing the drug to individuals, which may criminalize personal possession of mifepristone obtained from abroad, creating enforcement and privacy concerns.
- The bill does not specify what 'harm to mental health' includes in the liability section, creating ambiguity about what claims qualify and potentially opening providers to litigation over subjective psychological outcomes.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill restricts access to a FDA-approved medication by reverting to stricter dispensing rules and banning importation, reducing reproductive autonomy and healthcare options for patients. It also creates a private right of action that exposes healthcare providers and patients to civil liability, chilling lawful medical practice and potentially deterring providers from offering the medication.
Who stands to gain
- litigation funders and anti-abortion advocacy organizations (who may finance suits against providers
- law firms specializing in product liability and medical malpractice
Named in the bill
Secretary of Health and Human Services (HHS), FDA, mifepristone (Mifeprex, Korlym, RU-486), telehealth providers, pharmacies, Federal Food, Drug, and Cosmetic Act (FDCA), Section 505-1 (REMS authority), Section 1462 (title 18, USC — importation prohibition), Section 801 (FDCA — importation rules)
Where it stands
8 cosponsors: 8 Republicans.
- Sep 30, 2025 — Introduced · Congress.gov: “Introduced in House”
- Sep 30, 2025 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $420,000 in lobbying spend. A filing names 51 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Mary Miller, the sponsor, reported $145,130 in PAC receipts in the 2026 cycle.
- Susan B Anthony List — $420,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,094 characters) on Aug 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress moves to ban abortion pill and sue providers into silence” QuorumCivic. https://share.quorumcivic.app/bill/119/hr5646 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.